Prostate Cancer

Genetic Variant Predicts Faster Time to Prostate Cancer Metastasis

Genetic Variant Predicts Faster Time to Prostate Cancer Metastasis

By

The variant HSD3B1 allele increases the likelihood of metastasis in men receiving androgen-deprivation therapy for biochemically recurrent disease after radiotherapy for localized PCa.

Men With PCa Most Likely to Die From Other Causes

Men With PCa Most Likely to Die From Other Causes

By

Non-metastatic prostate cancer patients are more likely to die from causes other than the disease.

Prostate Cancer Hormone Therapy Ups Cardiac Risks

Prostate Cancer Hormone Therapy Ups Cardiac Risks

By

Exposure to androgen-deprivation therapy was associated with a nearly 2-fold increased risk of heart failure among men without pre-existing cardiovascular disease.

Clinicians Embrace New Prostate Cancer Grading System

Clinicians Embrace New Prostate Cancer Grading System

By

Endorsed by the International Society of Urological Pathology in 2014, the 5-tier Gleason grade group system is used routinely today in pathology reports and physician counseling of patients with newly diagnosed prostate cancer.

Overuse of Prostate Cancer Scans May Be Easing

Overuse of Prostate Cancer Scans May Be Easing

By

Efforts by physician groups in recent years to discourage inappropriate use of radiologic imaging for the initial staging of men with newly diagnosed low-risk disease possibly paying off.

Brachytherapy + EBRT for High-Risk PCa Offers 'Excellent' Outcomes

Brachytherapy + EBRT for High-Risk PCa Offers 'Excellent' Outcomes

By

Biochemical failure and prostate cancer-specific mortality rates were 13.3% and 4.9% at 10 years, respectively.

Prostate Cancer Pathologic Stage Alone Independently Predicts BCRFS

Prostate Cancer Pathologic Stage Alone Independently Predicts BCRFS

By

Pathologic stages T3a and T3b versus T2a were associated with 8.45 and 7.1 times increased risk of biochemical recurrence on multivariable analysis.

Testosterone Patterns Predict Prostate Cancer Risk

Testosterone Patterns Predict Prostate Cancer Risk

By

The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.

<i>BRCA2</i> Mutations Tied With Poor Survival, Progression in mCRPC

BRCA2 Mutations Tied With Poor Survival, Progression in mCRPC

Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.

IMRT for Prostate Cancer Radiation Therapy Soars

IMRT for Prostate Cancer Radiation Therapy Soars

By

Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.

Prostate Cancer Risk Lower in NSAID Users

Prostate Cancer Risk Lower in NSAID Users

By

In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.

Prostate Cancer Active Surveillance Use Low, But Increasing

Prostate Cancer Active Surveillance Use Low, But Increasing

By

Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.

First Metastasis Site Predicts Prostate Cancer-Specific Survival

First Metastasis Site Predicts Prostate Cancer-Specific Survival

By

Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.

Additions to Standard Care in High-Risk PCa May Up Survival

Additions to Standard Care in High-Risk PCa May Up Survival

Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.

New Prostate Cancer Biomarkers Can Improve Precision Therapy

New Prostate Cancer Biomarkers Can Improve Precision Therapy

Mutations in the SPOP gene aide in the development of BET-inhibitors resistance.

Proximal PSA Predicts Prostate Cancer Metastasis Risk

Proximal PSA Predicts Prostate Cancer Metastasis Risk

By

PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.

Toxicity Similar for 6- and 2- Fraction HDR Brachytherapy in PCa

Toxicity Similar for 6- and 2- Fraction HDR Brachytherapy in PCa

The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores.

Prostate Cancer Screening Saves Lives, New Analysis Shows

Prostate Cancer Screening Saves Lives, New Analysis Shows

By

A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.

The Role of MRI in Prostate Cancer Management

An interview with Ashutosh K. Tewari, MBBS, MCh

Prostate Cancer ADT Linked With Cardiovascular Risks, Depression

Prostate Cancer ADT Linked With Cardiovascular Risks, Depression

By

In a study, the risk for heart failure was 81% higher among patients who received androgen deprivation therapy.

Urologist Ownership of IMRT Linked to Its Greater Use for PCa

Urologist Ownership of IMRT Linked to Its Greater Use for PCa

By

Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.

Short-term Arterial Thromboembolism Risk Elevated in Cancer Patients

Short-term Arterial Thromboembolism Risk Elevated in Cancer Patients

The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.

Cancer Patient Self-Reporting Reliable and Feasible, Studies Show

Cancer Patient Self-Reporting Reliable and Feasible, Studies Show

By

Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.

Osteoporosis Drugs Up Bone Mineral Density in Nonmetastatic PCa

Osteoporosis Drugs Up Bone Mineral Density in Nonmetastatic PCa

Improvement in BMD was seen with denosumab, which also reduced the incidence of new radiographic vertebral fractures in one high-quality trial.

Not All High-Risk Prostate Cancers Are the Same

Not All High-Risk Prostate Cancers Are the Same

By

Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.

Blacks Less Likely to Undergo Definitive Prostate Cancer Therapy

Blacks Less Likely to Undergo Definitive Prostate Cancer Therapy

By

Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

By

A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.

Positive Lymph Node Prostate Cancer Care Patterns Characterized

Positive Lymph Node Prostate Cancer Care Patterns Characterized

By

63% of patients were managed initially with observation.

Active Surveillance for Intermediate-Risk PCa May Be Unsafe

Active Surveillance for Intermediate-Risk PCa May Be Unsafe

By

Nearly 1 in 3 patients diagnosed with Gleason 3+4 favorable intermediate-risk prostate cancer had their disease upgraded or upstaged at radical prostatectomy.

Top Complaint After Prostate Biopsy Is Infection

Top Complaint After Prostate Biopsy Is Infection

Most common infection in prostate biopsy was E. coli, followed by mild bleeding.

Sign Up for Free e-newsletters